Last updated: March 2026
MOTS-c is a 16-amino acid mitochondrial-derived peptide, discovered in 2015 by Dr. Pinchas Cohen's lab at USC, that acts as an exercise mimetic by activating AMPK — the cellular energy sensor. Research dosing is typically 10 mg via injection. It improves glucose metabolism, enhances physical performance, and reduces age-related metabolic decline in preclinical models.
MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) discovered in 2015 by Dr. Pinchas Cohen's lab at USC. It acts as an "exercise mimetic" — triggering metabolic effects similar to exercise.
MOTS-c activates AMPK (AMP-activated protein kinase), the same pathway activated by exercise. This triggers glucose uptake and metabolic reprogramming.
Called "exercise in a peptide," MOTS-c replicates many metabolic benefits of exercise without physical activity. Improves physical performance in mouse studies.
Improves glucose uptake in skeletal muscle and enhances insulin sensitivity. Shows promise for metabolic syndrome and type 2 diabetes.
MOTS-c levels decline with age. Supplementation may counteract age-related metabolic decline and mitochondrial dysfunction.
Preclinical and early human data on MOTS-c.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Support supplements for metabolic health.
Affiliate links help support MeetPeptide.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. MOTS-c is a research peptide not approved by the FDA. Most data comes from preclinical studies. Always consult a qualified healthcare provider before starting any new substance.